<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-040029</identifier>
<setSpec>0211-6995</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Renin-angiotensin system in diabetic nephropathy</dc:title>
<dc:description xml:lang="en">The importance of the renin angiotensin system (RAS) in the development andprogression of the diabetic nephropathy is confirmed with the recent demonstrationthat the development of nephropathy in the diabetic patients can be avoidedby blockers of the RAS. For that reason, the promotion of preventive programsfor the detection of microalbuminuria, from the early phases of thediabetes is needed. Control of blood pressure, of glucose and lipids are needed.If microalbuminuria is present, the administration of a blocker of RAS, even inthe presence of normal blood pressure can prevent the progression to diabeticnephropathy. The main objective to prevent the development and progressionof nephropathy in the diabetic patients, as well as the cardiovascular risk, is astrict control of the PA</dc:description>
<dc:creator>Luño, J</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La importancia atribuida al SRA en el desarrollo y progresión de la nefropatíadiabética se confirma con las evidencias recientes que demuestran que se puedeprevenir el desarrollo de nefropatía en los pacientes diabéticos mediante la intervenciónterapéutica con bloqueantes del SRA. Por ello, es necesaria la promociónde programas preventivos para la detección de microalbuminuria, desde las fasestempranas de la diabetes, que deben de incluir un adecuado control tensional,glucémico y lipídico. Si se detecta microalbuminuria, la administración de un bloqueantedel SRA, aún en presencia de cifras tensionales clásicamente consideradascomo normales puede prevenir la progresión a nefropatía diabética</dc:description>
<dc:source>Nefrologia;25(supl.2): 73-81, jun. 2005.</dc:source>
<dc:identifier>ibc-040029</dc:identifier>
<dc:title xml:lang="es">Sistema renina angiotensina en la nefropatía diabética</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d3951^s22062</dc:subject>
<dc:subject>^d1585^s22073</dc:subject>
<dc:subject>^d422^s22016</dc:subject>
<dc:subject>^d22832^s22000</dc:subject>
<dc:subject>^d1588^s22000</dc:subject>
<dc:subject>^d1585^s22000</dc:subject>
<dc:subject>^d33405^s22000</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d33405^s22073</dc:subject>
<dc:subject>^d31339^s22073</dc:subject>
<dc:subject>^d22832^s22073</dc:subject>
<dc:subject>^d22780</dc:subject>
<dc:subject>^d4419</dc:subject>
<dc:subject>^d12506^s22031</dc:subject>
<dc:subject>^d12506^s22021</dc:subject>
<dc:subject>^d962^s22000</dc:subject>
<dc:subject>^d1588^s22073</dc:subject>
<dc:subject>^d38265^s22000</dc:subject>
<dc:subject>^d962^s22073</dc:subject>
<dc:subject>^d3951^s22054</dc:subject>
<dc:subject>^d3951^s22032</dc:subject>
<dc:subject>^d38265^s22073</dc:subject>
<dc:type>article</dc:type>
<dc:date>200506</dc:date>
</metadata>
</record>
</ibecs-document>
